The U.S. Food and Drug Administration approved Incyte’s pemigatinib (Pemazyre) on Friday for previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. A rare cancer of the bile ducts, Cholangiocarcinoma occurs in...
Agios Pharmaceuticals announced that the global Phase 3 ClarIDHy trial of Tibsovo (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation met its primary endpoint. Treatment with Tibsovo demonstrated a...
